27687-14-5

Usage

Chemical Properties

White powder

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 108-20-3 di-isopropyl ether 
• 1197-17-7 4-aminomethyl-cyclohexanecarboxylic acid 
• 77-92-9 citric acid 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 87589-21-7 4-(tert-Butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid 2,2-dimethyl-propionyloxymethyl ester 
• 87589-31-9 4-(tert-Butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid isobutyryloxymethyl ester 
• 87589-44-4 (N,N-dimethylcarbamoyl)methylene bismethyl>cyclohexanecarboxylate> 
• 87611-42-5 C₃₀H₅₀N₂O₁₀ 
• 100165-57-9 (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl trans-4-<<(tert-butoxycarbonyl)amino>methyl>cyclohexanecarboxylate 
• 138865-34-6 ((S)-7-(4-Benzoyl-phenoxy)-5-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-6-oxo-heptyl)-carbamic acid benzyl ester 
• 263272-46-4 C₁₈H₃₁NO₆ 
• 325464-67-3 carbonic acid 4-[2-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-2-(3-methyl-butylcarbamoyl)-ethyl]-phenyl ester pyridin-4-ylmethyl ester 
• 325464-68-4 (4-{1-octylcarbamoyl-2-[4-(pyridin-4-ylmethoxy)-phenyl]-ethylcarbamoyl}-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 325464-66-2 carbonic acid 4-(2-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-2-octylcarbamoyl-ethyl)-phenyl ester pyridin-4-ylmethyl ester 
• 325464-70-8 4-[4-(2-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-2-octylcarbamoyl-ethyl)-phenoxymethyl]-benzoic acid methyl ester 
• 325464-41-3 Boc-Tra-Tyr(O-Pic)-NH-(CH₂)7-NH-Boc 
• 325464-30-0 Boc-Tra-Tyr(O-Pic)-NH(CH₂)7-COOPac 
• 395062-95-0 (4-{1-(4-ethyl-phenylcarbamoyl)-2-[4-(pyridin-4-ylmethoxy)-phenyl]-ethylcarbamoyl}-cyclohexylmethyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

ortho-Phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate

Provided herein are novel ortho-Phthalaldehyde (OPA) containing linkers (OPA-L) and the use of OPA-L for the preparation of Antibody-drug conjugate (ADC) via the formation of Phthalimidine through the reaction of primary amine on antibody (e.g., residue o

MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS

A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification

Decomposition of 1-(ω-aminoalkanoyl)guanidines under alkaline conditions

The decomposition of some NG-(ω-aminoalkanoyl)argininamides, which are key intermediates for the preparation of radiolabeled and fluorescent neuropeptide Y receptor ligands, prompted us to synthesize a small series of simple 1-(ω-aminoalkanoyl)guanidines, and to investigate these model compounds for stability in alkaline buffers. The degradation of acylguanidines was monitored by time resolved UV spectroscopy. The most labile compound, 1-(5-aminopentanoyl)guanidine, decomposed with a half life of 19 s to yield piperidin-2-one (pH 10.4 at 25 °C). In contrast the half life of 1-(6-aminohexanoyl)guanidine is 7.7 h, which is comparable to the hydrolysis of acetylguanidine (t1/2 = 9.6 h) in alkaline solution.

Halogenated sulfonamide derivatives

This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutic

Pyrimidine compounds

This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.

Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1

A series of 4-(dimethylamino)quinazoline based antagonists of the melanin-concentrating hormone receptor 1 (MCH-R1) is described. This series was derived from a lead compound, AR129330, identified by HTS of a GPCR-directed library using a functional assay with a constitutively activated (CART) form of the receptor. The preliminary optimization resulted in the identification of compounds 20, 21, and 23.

Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator

In this letter we report the synthesis and biochemical evaluation of selective, irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator (uPA). A diphenyl phosphonate group was introduced on the substratelike peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated. A guanylated benzyl group appeared the most promising side chain modification. A kapp value in the 103 M -1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.

NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME

The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.

Fused imidazopyridine derivatives as antihyperlipidemic agents

A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1and R2is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0is a bond or an optionally substituted bivalent hydrocarbon group; Z0is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3is hydrogen or an optionally substituted hydrocarbon group), or S(O)n(wherein n is to 0, 1 or 2); .........is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.